NASDAQ · SNCE
Science 37 Holdings, Inc.
$5.75+$0.02 (+0.35%)
Science 37 Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.63% below the high.
Loading market information…
NASDAQ · AKLI · USD
Stock price, earnings
Quote as of Jul 1, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Akili, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.35% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Akili, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Akili, Inc. is a digital medicine enterprise focused on developing innovative digital therapies for individuals experiencing cognitive impairments. Its flagship product, EndeavorRx, stands out as a unique video game-based treatment that necessitates a physician's prescription and is specifically engineered to directly target and improve cognitive functioning. This company operates from its headquarters in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:08 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2022 |
|---|
| Nov 14, 2022 |
| -$0.27-35.0% vs estimate |
| $82.00K |
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.75+$0.02 (+0.35%)
Science 37 Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.63% below the high.
CA$0.45-CA$0.02 (-3.26%)
Rocket Doctor AI Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.59% below the high.
$5.33$0.00 (0.0%)
Streamline Health Solutions, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.56% below the high.
$0.08$0.00 (0.0%)
Renalytix Plc’s quoted price sits in the lower half of its reported 52-week range, 87.52% below the high.
$0.23-$0.00 (-1.74%)
Think Research Corporation’s quoted price sits in the lower half of its reported 52-week range, 37.24% below the high.
$0.33-$0.03 (-8.71%)
Nurosene Health Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.73% below the high.
$0.50+$0.48 (+2,269.67%)
HealthBeacon plc’s quoted price sits in the lower half of its reported 52-week range, 82.76% below the high.
$0.03+$0.03 (0.0%)
Carebook Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.51% below the high.
